Does ATEZOLIZUMAB Cause Second primary malignancy? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Second primary malignancy have been filed in association with ATEZOLIZUMAB (Tecentriq Hybreza). This represents 0.0% of all adverse event reports for ATEZOLIZUMAB.
14
Reports of Second primary malignancy with ATEZOLIZUMAB
0.0%
of all ATEZOLIZUMAB reports
4
Deaths
4
Hospitalizations
How Dangerous Is Second primary malignancy From ATEZOLIZUMAB?
Of the 14 reports, 4 (28.6%) resulted in death, 4 (28.6%) required hospitalization, and 2 (14.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ATEZOLIZUMAB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does ATEZOLIZUMAB Cause?
Death (3,591)
Off label use (2,340)
Disease progression (1,828)
Pyrexia (1,599)
Diarrhoea (1,490)
Fatigue (1,253)
Anaemia (1,195)
Pneumonia (1,036)
Nausea (953)
Dyspnoea (938)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ATEZOLIZUMAB Alternatives Have Lower Second primary malignancy Risk?
ATEZOLIZUMAB vs ATLANTIC SALMON OIL
ATEZOLIZUMAB vs ATOGEPANT
ATEZOLIZUMAB vs ATOMOXETINE
ATEZOLIZUMAB vs ATOMOXETINE\ATOMOXETINE
ATEZOLIZUMAB vs ATORVASTATIN